Antidepressant utilization patterns and mortality in Swedish men and women aged 20-34 years

European Journal of Clinical Pharmacology

Volumn 67, Issue 2, 2011, Pages 169-178

  Andersson Sundell, Karolina ^a   Gissler, Mika ^a,b   Petzold, Max ^a   Waern, Margda ^c,d  

^a NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Antidepressants; Mood stabilizers; Mortality; Swedish Prescribed Drug Register; Utilization; Young adults

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; LAMOTRIGINE; LITHIUM; MIANSERIN; MIRTAZAPINE; MOCLOBEMIDE; MOOD STABILIZER; NEUROLEPTIC AGENT; PAROXETINE; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; DRUG SUBSTITUTION; DRUG USE; DRUG UTILIZATION; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT COMPLIANCE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SWEDEN;

ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MORTALITY; SEX FACTORS; SWEDEN; YOUNG ADULT;

EID: 79151481388     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-010-0933-z     Document Type: Article

References (35)

1. CJ Murray AD Lopez 1997 Alternative projections of mortality and disability by cause 1990-2020: global burden of disease study Lancet 349 1498 1504 10.1016/S0140-6736(96)07492-2 1:STN:280:DyaK2szhtVaqsw%3D%3D 9167458
2. MH Pollack 2005 Comorbid anxiety and depression J Clin Psychiatry 66 Suppl 8 22 29 1:CAS:528:DC%2BD28Xis1E%3D 16336033
3. NM Simon 2009 Generalized anxiety disorder and psychiatric comorbidities such as depression, bipolar disorder, and substance abuse J Clin Psychiatry 70 Suppl 2 10 14 19371501
4. P Sobocki M Ekman H Agren I Krakau B Runeson B Martensson B Jonsson 2007 Health-related quality of life measured with EQ-5D in patients treated for depression in primary care Value Health 10 153 160 10.1111/j.1524-4733.2006. 00162.x 17391424
5. P Sobocki I Lekander F Borgstrom O Strom B Runeson 2007 The economic burden of depression in Sweden from 1997 to 2005 Eur Psychiatry 22 146 152 10.1016/j.eurpsy.2006.10.006 17194573
6. P Sobocki M Ekman H Agren B Runeson B Jonsson 2006 The mission is remission: health economic consequences of achieving full remission with antidepressant treatment for depression Int J Clin Pract 60 791 798 10.1111/j.1742-1241.2006.00997.x 1:STN:280:DC%2BD28visV2ntw%3D%3D 16846399
7. CA Beck SB Patten JV Williams JL Wang SR Currie CJ Maxwell N El-Guebaly 2005 Antidepressant utilization in Canada Soc Psychiatry Psychiatr Epidemiol 40 799 807 16179967
8. S Henriksson R Asplund G Boethius T Hallstrom G Isacsson 2006 Infrequent use of antidepressants in depressed individuals (an interview and prescription database study in a defined Swedish population 2001-2002) Eur Psychiatry 21 355 360 10.1016/j.eurpsy.2006.04.003 1:STN:280:DC%2BD28rlslSrtw%3D%3D 16777386
9. G Isacsson G Boethius S Henriksson JK Jones U Bergman 1999 Selective serotonin reuptake inhibitors have broadened the utilisation of antidepressant treatment in accordance with recommendations. Findings from a Swedish prescription database J Affect Disord 53 15 22 1:STN:280:DyaK1M3ptVegsg%3D%3D 10363662
10. M Kivimaki D Gunnell DA Lawlor G Davey Smith J Pentti M Virtanen M Elovainio T Klaukka J Vahtera 2007 Social inequalities in antidepressant treatment and mortality: a longitudinal register study Psychol Med 37 373 382 10.1017/S0033291706009457 17121686
11. M Percudani C Barbui I Fortino L Petrovich 2004 Antidepressant drug use in Lombardy, Italy: a population-based study J Affect Disord 83 169 175 10.1016/j.jad.2004.07.005 15555710
12. DG Hansen W Vach JU Rosholm J Sondergaard LF Gram J Kragstrup 2004 Early discontinuation of antidepressants in general practice: association with patient and prescriber characteristics Fam Pract 21 623 629 15520034
13. EC van Geffen R van Hulten ML Bouvy AC Egberts ER Heerdink 2008 Characteristics and reasons associated with nonacceptance of selective serotonin-reuptake inhibitor treatment Ann Pharmacother 442 218 225 10.1345/aph.1K516
14. D Osborn G Levy I Nazareth M King 2008 Suicide and severe mental illnesses. Cohort study within the UK general practice research database Schizophr Res 99 134 138 10.1016/j.schres.2007.11.025 18155881
15. RJ Valuck HD Orton AM Libby 2009 Antidepressant discontinuation and risk of suicide attempt: a retrospective, nested case-control study J Clin Psychiatry 70 1069 1077 10.4088/JCP.08m04943 19758520
16. J Haukka J Tiihonen T Harkanen J Lonnqvist 2008 Association between medication and risk of suicide, attempted suicide and death in nationwide cohort of suicidal patients with schizophrenia Pharmacoepidemiol Drug Saf 17 686 696 10.1002/pds.1579 18327869
17. J Tiihonen J Lonnqvist K Wahlbeck T Klaukka A Tanskanen J Haukka 2006 Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort Arch Gen Psychiatry 63 1358 1367 10.1001/archpsyc.63.12.1358 1:CAS:528:DC%2BD2sXislGqtw%3D%3D 17146010
18. Andersson L (2006) Regional differences in disability pension and sickness absence with psychiatric diagnoses in Sweden and Norway 1980-2000: the influence of demography and access to psychiatric health care. Dissertation. The Sahlgrenska Academy at Göteborg University, Department of Public Health and Community Medicine, Gothenburg
19. B Wettermark N Hammar CM Fored A Leimanis P Otterblad Olausson U Bergman I Persson A Sundstrom B Westerholm M Rosen 2007 The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months Pharmacoepidemiol Drug Saf 16 726 735 10.1002/pds.1294 16897791
20. Anonymous (2002) Anatomical Therapeutic Chemical (ATC) Classification Index. WHO Collaborating Centre for Drug Statistics Methodology, Geneva
21. Act (2002:160) on Pharmaceutical Benefits, etc. In SFS 2002:160
22. JU Rosholm M Andersen LF Gram 2001 Are there differences in the use of selective serotonin reuptake inhibitors and tricyclic antidepressants? A prescription database study Eur J Clin Pharmacol 56 923 929 1:CAS:528: DC%2BD3MXitFehsrc%3D 11317482
23. JU Rosholm LF Gram G Isacsson J Hallas U Bergman 1997 Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study Eur J Clin Pharmacol 52 205 209 1:CAS:528:DyaK2sXktF2it7g%3D 9218927
24. JM Zito H Tobi LT de Jong-van den Berg JM Fegert DJ Safer K Janhsen DG Hansen JF Gardner G Glaeske 2006 Antidepressant prevalence for youths: a multi-national comparison Pharmacoepidemiol Drug Saf 15 793 798 10.1002/pds.1254 1:CAS:528:DC%2BD28Xhtlartb7J 16715536
25. T Kairuz I Truter J Hugo C Foxcroft 2003 Prescribing patterns of tricyclic and selective serotonin reuptake inhibitor antidepressants among a sample of adolescents and young adults Pharmacoepidemiol Drug Saf 12 379 382 10.1002/pds.854 12899111
26. J Haukka M Arffman T Partonen S Sihvo M Elovainio J Tiihonen J Lonnqvist I Keskimaki 2009 Antidepressant use and mortality in Finland: a register-linkage study from a nationwide cohort Eur J Clin Pharmacol 65 715 720 10.1007/s00228-009-0616-9 19259654
27. L Sondergard K Kvist PK Andersen LV Kessing 2006 Do antidepressants prevent suicide? Int Clin Psychopharmacol 21 211 218 16687992
28. L Sondergard AG Lopez PK Andersen LV Kessing 2007 Continued antidepressant treatment and suicide in patients with depressive disorder Arch Suicide Res 11 163 175 10.1080/13811110701249889 17453694
29. EG Smith L Sondergard AG Lopez PK Andersen LV Kessing 2009 Association between consistent purchase of anticonvulsants or lithium and suicide risk: a longitudinal cohort study from Denmark, 1995-2001 J Affect Disord 10.1016/j.jad.2009.01.013
30. L Sondergard AG Lopez PK Andersen LV Kessing 2008 Mood-stabilizing pharmacological treatment in bipolar disorders and risk of suicide Bipolar Disord 10.1111/j.1399-5618.2008.00464.x 18199245
31. E Patorno RL Bohn PM Wahl J Avorn AR Patrick J Liu S Schneeweiss 2010 Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death JAMA 303 1401 1409 10.1001/jama.2010.410 1:CAS:528: DC%2BC3cXksl2hsL8%3D 20388896
32. H Gardarsdottir EC van Geffen JJ Stolker TC Egberts ER Heerdink 2009 Does the length of the first antidepressant treatment episode influence risk and time to a second episode? J Clin Psychopharmacol 29 69 72 10.1097/JCP. 0b013e31819302b1 1:CAS:528:DC%2BD1MXkvVSitQ%3D%3D 19142111
33. H Gardarsdottir ER Heerdink AC Egberts 2006 Potential bias in pharmacoepidemiological studies due to the length of the drug free period: a study on antidepressant drug use in adults in the Netherlands Pharmacoepidemiol Drug Saf 15 338 343 10.1002/pds.1223 16496430
34. H Gardarsdottir ER Heerdink L van Dijk AC Egberts 2007 Indications for antidepressant drug prescribing in general practice in the Netherlands J Affect Disord 98 109 115 10.1016/j.jad.2006.07.003 1:STN:280:DC%2BD2s%2Fit1WmtA%3D%3D 16956665
35. S Henriksson G Boethius J Hakansson G Isacsson 2003 Indications for and outcome of antidepressant medication in a general population: a prescription database and medical record study, in Jamtland county, Sweden, 1995 Acta Psychiatr Scand 108 427 431 1:STN:280:DC%2BD3srjs1arug%3D%3D 14616223